Search
Invitrogen
Sirolimus Recombinant Mouse Monoclonal Antibody (4G8)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
FIGURE: 1 / 1
Sirolimus Antibody (MA566318) in SDS-PAGE
SDS-PAGE characterization of Sirolimus under reducing conditions. Lane M: Protein marker (kDa); Lane SRL: Purified Sirolimus Recombinant Monoclonal (Product # MA566318). Sirolimus showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-327.
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Product Details
MA566318
Product Specifications
Species Reactivity
Chemical
Host/Isotype
Mouse
/ IgG
Expression System
CHO cells
Class
Recombinant Monoclonal
Type
Antibody
Clone
4G8
Immunogen
Conjugate of SRL hapten and KLH.
Conjugate
Unconjugated
Unconjugated
Unconjugated
Form
Liquid
Concentration
11 mg/mL
Amount
200 µg
Purification
Protein G
Storage buffer
PBS
Contains
0.09% sodium azide
Storage conditions
-20°C
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
Target Information
Sirolimus, also known as rapamycin, is a macrolide compound with potent immunosuppressive properties, primarily used to prevent organ transplant rejection. It functions by inhibiting the mechanistic target of rapamycin (mTOR), a key regulatory kinase involved in cell proliferation and survival. Sirolimus is often utilized in drug-eluting stents, such as the BioMime sirolimus-eluting stent, to prevent restenosis in coronary arteries. The drug's gene location and structure are not directly relevant, as it is a synthetic compound rather than a naturally occurring gene product. However, its mechanism of action involves binding to the FKBP12 protein, forming a complex that inhibits mTOR signaling pathways, thereby reducing T-cell and B-cell proliferation. Sirolimus has been extensively studied for its efficacy in prolonging allograft survival and reversing acute rejection in animal models, leading to its approval for clinical use in renal transplant prophylaxis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support